Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

Osteoporosis International

Volumn 21, Issue 12, 2010, Pages 2013-2018

  Kanazawa, I ^a   Yamaguchi, T ^a   Yano, S ^a   Yamamoto, M ^a   Yamauchi, M ^a   Kurioka, S ^a   Sugimoto, T ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Bone mineral density; Metformin; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIOLOGICAL MARKER; COLLAGEN TYPE 1; INSULIN; METFORMIN; N TERMINAL CROSS LINKED TELOPEPTIDE OF TYPE 1 COLLAGEN; OSTEOCALCIN; PIOGLITAZONE; SOMATOMEDIN C; SULFONYLUREA; UNCLASSIFIED DRUG;

AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE ATROPHY; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FEMUR NECK; HUMAN; JAPANESE; LUMBAR SPINE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; BONE DENSITY; COLLAGEN; DIABETES MELLITUS, TYPE 2; FEMALE; FEMUR NECK; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; LUMBAR VERTEBRAE; MALE; METFORMIN; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; RADIUS; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 78549253802     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1161-1     Document Type: Article

References (20)

1. B Richter E Banderia-Echtler K Bergerhoff C Clar SH Ebrahim 2006 Pioglitazone for type 2 diabetes mellitus Cochrane Database Syst Rev 18 CD006060
2. B Richter E Banderia-Echtler K Bergerhoff C Clar SH Ebrahim 2007 Rosiglitazone for type 2 diabetes mellitus Cochrane Database Syst Rev 18 CD006063
3. AA Ali RS Weinstein SA Stewart AM Parfitt SC Manolagas RI Jilka 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 1226 1235 1:CAS:528:DC%2BD2MXitlehtro%3D 10.1210/en.2004-0735 15591153 (Pubitemid 40289310)
4. T Akune S Ohba S Kamekura M Yamaguchi C U-i N Kubota Y Terauchi Y Harada Y Azuma K Nakamura T Kadowaki H Kawaguchi 2004 PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors J Clin Invest 113 846 855 1:CAS:528:DC%2BD2cXisVagtbw%3D 15067317
5. YK Loke S Singh CD Furberg 2009 Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ 180 32 39 19073651
6. A Grey M Bolland G Gamble D Wattie A Horne J Davidson IR Reid 2007 The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 92 1305 1310 1:CAS:528:DC%2BD2sXksVSrtr4%3D 10.1210/jc.2006-2646 17264176 (Pubitemid 46556402)
7. D Glintborg M Andersen C Hagen L Heickendorff AP Hermann 2008 Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial J Clin Endocrinol Metab 93 1696 1701 1:CAS:528:DC%2BD1cXlvFWgs70%3D 10.1210/jc.2007-2249 18285411 (Pubitemid 351656507)
8. I Kanazawa T Yamaguchi S Yano M Yamauchi T Sugimoto 2008 Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression Biochem Biophys Res Commun 375 414 419 1:CAS:528:DC%2BD1cXhtFaqs7nE 10.1016/j.bbrc.2008.08.034 18721796
9. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Yano T Sugimoto 2007 Serum insulin-like growth factor-I is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus Osteoporos Int 18 1675 1681 1:CAS:528:DC%2BD2sXhtF2ht7nN 10.1007/s00198-007-0430-0 17632742 (Pubitemid 47620319)
10. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Yano T Sugimoto 2008 Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men Calcif Tissue Int 83 324 331 1:CAS:528:DC%2BD1cXhtlWhsLbN 10.1007/s00223-008-9178-6 18946627
11. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Kurioka S Yano T Sugimoto 2008 Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus Endocr J 55 667 675 1:CAS:528:DC%2BD1cXhsVaqtrvN 10.1507/endocrj.K07E-130 18493102
12. I Kanazawa T Yamaguchi M Yamamoto M Yamauchi S Kurioka S Yano T Sugimoto 2009 Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus J Clin Endocrinol Metab 94 45 49 1:CAS:528:DC%2BD1MXptVKmtA%3D%3D 10.1210/jc.2008-1455 18984661
13. SI McFarlane R Muniyappa JJ Shin G Bathtiyar JR Sowers 2004 Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23 1 10 1:CAS:528:DC%2BD2cXjsVyktL4%3D 10.1385/ENDO:23:1:01 15034190
14. P von der Recke MA Hansen C Hassager 1999 The association between low bone mass at the menopause and cardiovascular mortality Am J Med 106 273 278 10.1016/S0002-9343(99)00028-5 10190374 (Pubitemid 29153403)
15. JA Dormandy B Charbonnel DJ Eckland E Erdmann M Massi-Benedetti IK Moules AM Skene MH Tan PJ Lefebvre GD Murray E Standi RG Wilcox L Wilhelmsen J Betteridge K Birkeland A Golay RJ Heine L Koranyi M Laakso M Mokan A Norkus V Pirags T Podar A Scheen W Scherbaum G Shernthaner O Schmitz J Skrha U Smith J Taton PROactive Investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: a randomized controlled trial Lancet 366 1279 1289 1:CAS:528:DC%2BD2MXhtVOlu7fO 10.1016/S0140-6736(05) 67528-9 16214598 (Pubitemid 41416583)
16. TL McCarthy M Centrella E Canalis 1989 Insulin-like growth factor (IGF) and bone Connect Tissue Res 20 277 282 1:STN:280:DyaK3c7isFKnsA%3D%3D 10.3109/03008208909023897 2692956
17. S Yakar CJ Rosen WG Beamer CL Ackert-Bicknell Y Wu JL Liu GT Ooi J Setser J Frystyk YR Boisclair D LeRoith 2002 Circulating levels of IGF-I directly regulate bone growth and density J Clin Invest 110 771 781 1:CAS:528: DC%2BD38Xnt1ehtLc%3D 12235108
18. T Yamaguchi M Kanatani M Yamauchi H Kaji T Sugishita DJ Baylink S Mohan K Chihara T Sugimoto 2006 Serum levels of insulin-like growth factor (IGF); IGF-binding protein-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women Calcif Tissue Int 78 18 24 1:CAS:528:DC%2BD28XkvFOjsw%3D%3D 10.1007/s00223-005-0163-z 16397738 (Pubitemid 43107288)
19. LJ Melton 3rd CL Leibson SJ Achenbach TM Therneau S Khosla 2008 Fracture risk in type 2 diabetes: update of a population-based study J Bone Miner Res 23 1334 1342 10.1359/jbmr.080323 18348689 (Pubitemid 352040189)
20. WY Fujimoto 1996 Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups Diabet Med 13 S7 S10 1:STN:280: DyaK2s%2FkvFOntg%3D%3D 10.1002/(SICI)1096-9136(199601)13:1<7::AID-DIA74>3. 0.CO;2-P 8894472